Sanofi-Aventis has agreed to extend its research pact with the UK's ImmunoGen for two more years. In the final year of the pact, which begins September 1, 2007, ImmunoGen will get at least $10.4 million. ImmunoGen also gains the rights to develop new targets for antibody-based cancer drugs.
- read the AP report on the research deal